AstraZeneca recently launched a new health technology business called Evinova, which will leverage the company’s expertise in clinical trial design and study delivery. The Anglo-Swedish pharmaceutical giant intends to offer a wide range of solutions to trial sponsors, clinical research organizations, care teams and patients.
Evinova’s offering includes enhanced data collection and machine learning algorithms to support teams designing their studies. The goal is to reduce the time and costs of developing new drugs, bring care closer to patients’ homes and reduce the burden on healthcare systems. To expand the reach of Evin’s digital health solutions, the company has announced major collaborations with clinical research organizations Parekel and Fortrea.
AstraZeneca CEO Pascal Soriot expressed confidence in Evinova’s ability to make a significant impact on patient care, healthcare transformation, and carbon reduction. The company also highlighted the expected growth of the digital health market, predicting that it will be worth more than $900 billion by 2032.
For more information about Evinova or AstraZeneca’s digital health initiatives, please contact Michael Susin at email@example.com.